Arvinas, Inc. (ARVN): Price and Financial Metrics

Arvinas, Inc. (ARVN): $42.58

0.49 (+1.16%)

POWR Rating

Component Grades














  • Growth is the dimension where ARVN ranks best; there it ranks ahead of 46.8% of US stocks.
  • The strongest trend for ARVN is in Momentum, which has been heading down over the past 179 days.
  • ARVN ranks lowest in Sentiment; there it ranks in the 12th percentile.

ARVN Stock Summary

  • For ARVN, its debt to operating expenses ratio is greater than that reported by merely 7.02% of US equities we're observing.
  • ARVN's price/sales ratio is 76.76; that's higher than the P/S ratio of 97.11% of US stocks.
  • As for revenue growth, note that ARVN's revenue has grown 114.2% over the past 12 months; that beats the revenue growth of 92.79% of US companies in our set.
  • Stocks that are quantitatively similar to ARVN, based on their financial statements, market capitalization, and price volatility, are DNLI, IMTX, VRNA, ALLO, and ARGX.
  • Visit ARVN's SEC page to see the company's official filings. To visit the company's web site, go to

ARVN Valuation Summary

  • In comparison to the median Healthcare stock, ARVN's EV/EBIT ratio is 187.37% lower, now standing at -25.6.
  • ARVN's price/sales ratio has moved up 136.9 over the prior 36 months.
  • Over the past 36 months, ARVN's price/sales ratio has gone up 136.9.

Below are key valuation metrics over time for ARVN.

Stock Date P/S P/B P/E EV/EBIT
ARVN 2021-08-31 202.9 7.3 -25.9 -25.6
ARVN 2021-08-30 200.5 7.2 -25.6 -25.3
ARVN 2021-08-27 201.1 7.2 -25.7 -25.4
ARVN 2021-08-26 196.4 7.0 -25.1 -24.8
ARVN 2021-08-25 199.4 7.1 -25.5 -25.2
ARVN 2021-08-24 200.4 7.2 -25.6 -25.3

ARVN's Quality Factors

The “Quality” component of the POWR Ratings focuses on 31 different factors of a companies fundamentals and operational strength. Here are some key insights as we drill into the specifics of these quality attributes.
  • ARVN has a Quality Grade of D, ranking ahead of 9.31% of graded US stocks.
  • ARVN's asset turnover comes in at 0.036 -- ranking 344th of 681 Pharmaceutical Products stocks.
  • 500 - Internal server error

The table below shows ARVN's key quality metrics over time.

Period Asset Turnover Gross Margin ROIC
2021-06-30 0.036 1 -0.601
2021-03-31 0.044 1 -0.743
2020-12-31 0.057 1 -0.721
2020-09-30 0.088 1 -0.470
2020-06-30 0.178 1 -0.396
2020-03-31 0.187 1 -0.389

ARVN Price Target

For more insight on analysts targets of ARVN, see our ARVN price target page. And for a list of of all stocks sorted by upside potential based on analyst target price, see our Top Price Target page.

Average Price Target $130.77 Average Broker Recommendation 1.27 (Strong Buy)

ARVN Stock Price Chart Interactive Chart >

Price chart for ARVN

ARVN Price/Volume Stats

Current price $42.58 52-week high $108.46
Prev. close $42.09 52-week low $34.90
Day low $40.93 Volume 232,600
Day high $42.71 Avg. volume 470,853
50-day MA $45.29 Dividend yield N/A
200-day MA $67.88 Market Cap 2.26B

Arvinas, Inc. (ARVN) Company Bio

Arvinas Inc., a biopharmaceutical company, engages in the discovery, development, and commercialization of therapies to degrade disease-causing proteins. Its lead products include ARV-110, proteolysis targeting chimeras (PROTAC) targeting the androgen receptor (AR) protein for the treatment of men with metastatic castration-resistant prostate cancer; and ARV-471, a PROTAC targeting the estrogen receptor protein for the treatment of women with metastatic ER+ breast cancer. The company is also developing other PROTACs for degrading AR and other clinically relevant AR point mutations; and various other products for the treatment of neurodegenerative diseases, including tauopathies. Arvinas Holding Company, LLC was founded in 2015 and is based in New Haven, Connecticut.

ARVN Latest News Stream

Event/Time News Detail
Loading, please wait...

ARVN Latest Social Stream

Loading social stream, please wait...

View Full ARVN Social Stream

Latest ARVN News From Around the Web

Below are the latest news stories about Arvinas Inc that investors may wish to consider to help them evaluate ARVN as an investment opportunity.

Kymera Therapeutics, Inc. (KYMR) Reports Q4 Loss, Lags Revenue Estimates

Kymera Therapeutics, Inc. (KYMR) delivered earnings and revenue surprises of -83.33% and 27.78%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?

Yahoo | February 24, 2022

Arvinas PROTAC® Protein Degrader Bavdegalutamide (ARV-110) Continues to Demonstrate Clinical Benefit in Men with Metastatic Castration-Resistant Prostate Cancer

– Bavdegalutamide treatment demonstrated robust activity in molecularly defined tumors (androgen receptor T878X/H875Y), with a 46% PSA50 rate and durable RECIST responses – – Data support the potential for an accelerated approval pathway in a molecularly defined patient population, and the Company intends to initiate a pivotal trial by year end 2022 – – Anti-tumor activity seen across all subgroups of the ongoing Phase 2 ARDENT trial in patients who had progressed after treatment with novel horm

Yahoo | February 17, 2022

Despite shrinking by US$144m in the past week, Arvinas (NASDAQ:ARVN) shareholders are still up 227% over 3 years

It might seem bad, but the worst that can happen when you buy a stock (without leverage) is that its share price goes...

Yahoo | February 17, 2022

3 Stocks To Double Down On In 2022

The markets are entering somewhat uncertain territory, as the S&P 500 recently experienced its 39th correction since the beginning of 1950 due to a combination of the omicron fears, and the anticipation of the Fed raising rates to curb the surge of inflation. This has led to a growing concern about the possibility of a bear market this year. However, Goldman Sachs chief global equity strategist Peter Oppenheimer believes it''s time to buy. “Any further significant weakness at the index level should be seen as a buying opportunity, in our view, albeit with moderate upside through the year as a whole,” he recently wrote. Analysts at Goldman have set their sights on three stocks they believe will tower 70% or more this year: Arvinas Inc. (NASDAQ: ARVN ): Arvinas is a clinical-stage biophar...

Benzinga | February 16, 2022

Leerink Partners Maintains a Buy Rating on Arvinas Holding Company (ARVN)

In a report released today, Christopher Liu from Leerink Partners maintained a Buy rating on Arvinas Holding Company (ARVN – Research Report). The company's shares closed last Tuesday at $76.54. According to, Liu is ranked 0 out of 5 stars with an average return of -20.9% and a 20.0% success rate. Liu covers the Healthcare sector, focusing on stocks such as Monte Rosa Therapeutics, Nurix Therapeutics, and Cogent Biosciences. Currently, the analyst consensus on Arvinas Holding Company is a Strong Buy with an average price target of $134.40, implying a 77.9% upside from current levels.

Brian Anderson on TipRanks | February 15, 2022

Read More 'ARVN' Stories Here

ARVN Price Returns

1-mo -3.77%
3-mo -41.94%
6-mo -46.04%
1-year -46.70%
3-year 70.87%
5-year N/A
YTD -48.16%
2021 -3.29%
2020 106.69%
2019 219.77%
2018 N/A
2017 N/A

Continue Researching ARVN

Here are a few links from around the web to help you further your research on Arvinas Inc's stock as an investment opportunity:

Arvinas Inc (ARVN) Stock Price | Nasdaq
Arvinas Inc (ARVN) Stock Quote, History and News - Yahoo Finance
Arvinas Inc (ARVN) Stock Price and Basic Information | MarketWatch

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from!

Page generated in 0.652 seconds.